Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 78
Preparation of global filing of oral semaglutide expected
during 2019 pending successful completion of phase 3 trials
2018
2018
2018
2018
2016
2017
Q11 Q2¹ Q31 Q41
PIONEER 1: Monotherapy
PIONEER 2: vs empagliflozin
PIONEER 3: vs sitagliptin
2019
2020+
Trial
PIONEER 4: vs liraglutide
Filing
PIONEER 5: Moderate renal impairment
PIONEER 6: Cardiovascular outcomes²
PIONEER 7: Flexible dose escalation³
PIONEER 8: Insulin add-on
PIONEER 9: Japan monotherapy
PIONEER 10: Japan OAD combination
Potential launch
Preparation of
global filing
and
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement; 2 Trial to rule out cardiovascular risk; 3 To be followed by 52-week extension trial
Note: Estimated timing of trials from first patient first visit to last patient last visit and subsequent completion of trial
OAD: Oral anti-diabetic
Regulatory
decision
potential
launch
novo nordiskView entire presentation